FutureTech II Acquisition Corp. FTII
- Market cap
- $50.5M
- P/E
- 60.1×
Follow FTII
Target Price Range
Analyst price targets
Free account| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 9.95 |
Analyst estimates 2023–2025 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 10.50 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | 0 | 1 |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | 0 | — | — | — | 0 | 1 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | — | 0.05 |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | — | (0.04) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | — | (0.04) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 7.68 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | — | 15 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | (1) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | (1) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 0 | 115 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | (0.57%) | 1.17% |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (43.68%) |
ROE
|
|||
FutureTech II Acquisition Corp. peers in Shell Companies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BKHA Black Hawk Acquisition Corporation | $50.6M | — | Compare |
| ALCYF Alchemy Investments Acquisition Corp 1 | $49.7M | — | Compare |
| ALSAF Alpha Star Acquisition Corporation | $49.4M | 46.7× | Compare |
| EMCGF Embrace Change Acquisition Corp. | $53.6M | 56.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AOGO Arogo Capital Acquisition Corp. | $47.6M | 3.4× | Compare |
| YHNA YHN Acquisition I Limited | $47.6M | — | Compare |
| NBST Newbury Street Acquisition Corporation | $54.2M | 0.0× | Compare |
| CLRCF ClimateRock | $54.6M | 0.0× | Compare |
FutureTech II Acquisition Corp. (FTII) key facts
- FutureTech II Acquisition Corp. (FTII) is a Shell Companies company in the Financial sector.
- Net income was $700,000.00, or $0.05 per share (basic), a net margin of 0.00%.
- As of September 23, 2026, FTII traded at $12.02, a market capitalization of $50.5 million.
- At that price the stock trades at 60.1× trailing-twelve-month earnings.
- Return on equity was −43.7% and debt-to-equity 0.06.
FutureTech II Acquisition Corp. (FTII) Latest News
4 Dec
FutureTech II Acquisition Corp. received a deficiency notification letter from Nasdaq due to delayed filing of Quarterly Report on Form 10-Q and non-compliance with publicly held shares rule. The company is working towards regaining compliance. The delayed filing and non-compliance issues may moderately impact the company's financial performance and market sentiment.
20 Sep
Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. have announced a business combination to create a Nasdaq-listed biopharmaceutical company focused on advancing new technologies to promote human health and longevity. The business combination is expected to significantly impact FutureTech II Acquisition Corp.'s future and market performance by expanding its operations into the biopharmaceutical sector.